Sanofi, Sobi: Positive topline results from pivotal phase 3 study of in children under 12 with haemophilia A

 

• Primary endpoint was met with no factor VIII inhibitors detected, confirming the safety profile of efanesoctocog alfa in previously treated patients under 12 years of age
• The completion of XTEND-Kids represents the final milestone needed for regulatory submission in the EU

https://www.biospace.com/article/releases/positive-topline-results-from-pivotal-xtend-kids-phase-3-study-of-efanesoctocog-alfa-in-children-under-12-years-of-age-with-haemophilia-a-swedish-orphan-biovitrum-ab/